Treatment Approaches for Resectable Stage-III NSCLC in the Adjuvant Setting

Opinion
Video

Vinay Raja, MD, explores the crucial role of adjuvant immunotherapy in resectable stage III NSCLC, providing insights into patient selection criteria, considerations for choosing among available treatment options, and the impact of recent trial data updates on informing treatment decisions in this evolving therapeutic landscape.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Stage IV lung cancer may be curable based on the success of the DREAM Program, according to thoracic surgeon, Ankit Bharat, MBBS,
Ankit Bharat, MBBS, a thoracic surgeon, discussed potential treatment emergent adverse effects or complications, as well as strategies for managing them.
Thoracic surgeon, Ankit Bharat, MBBS, discussed surgical strategies among patients with advanced lung cancer diagnoses based on staging.
In a CancerNetwork® YouTube video, Cornelia Tischmacher, a mother of twins from Germany, outlined her receipt of double lung transplantation.
2 experts in this video
2 experts in this video
2 experts in this video
2 experts in this video
Treatment with lorlatinib might be effective regardless of the presence of central nervous system metastases, according to Misako Nagasaka, MD, PhD.
Most central nervous system events with lorlatinib were grade 1 or 2 in the phase 3 CROWN trial.
Related Content
Following the induction phase with chemotherapy alone, ibrilatazar has shown a manageable toxicity profile in patients with advanced squamous NSCLC.

Ibrilatazar Shows Survival Improvement in Advanced Squamous NSCLC

Roman Fabbricatore
June 6th 2025
Article

Following the induction phase with chemotherapy alone, ibrilatazar has shown a manageable toxicity profile in patients with advanced squamous NSCLC.

The “inescapability” of climate hazards may necessitate prioritization of research to improve outcomes among vulnerable populations who require treatment.

Improving NSCLC Surgery Recovery After Climate Disaster Exposure

Leticia Nogueira, PhD, MPH
March 31st 2025
Podcast

The “inescapability” of climate hazards may necessitate prioritization of research to improve outcomes among vulnerable populations who require treatment.

Among 44 patients with EGFR-positive non–small cell lung cancer who discontinued docetaxel, 36.4% crossed over to the sac-TMT arm.

Sacituzumab Tirumotecan Improves Response vs Docetaxel in EFGR+ NSCLC

Ashley Chan
June 5th 2025
Article

Among 44 patients with EGFR-positive non–small cell lung cancer who discontinued docetaxel, 36.4% crossed over to the sac-TMT arm.

Experts from Washington University in St. Louis discuss trial results and infusion-related reaction management for amivantamab in EGFR-mutated NSCLC.

Navigating Management and Dosing Considerations for Amivantamab in NSCLC

Daniel Morgensztern, MD;Mary Ellen Flanagan, NP ;Janelle Mann, PharmD, BCOP
February 10th 2025
Podcast

Experts from Washington University in St. Louis discuss trial results and infusion-related reaction management for amivantamab in EGFR-mutated NSCLC.

The DREAM program led by Ankit Bharat, MD, MBBS, FACS, allowed Cornelia Tischmacher to receive a double lung transplant for her stage IV lung cancer.

An International Search for Lung Cancer Treatment Leads to Double Lung Transplant

Roman Fabbricatore
June 4th 2025
Article

The DREAM program led by Ankit Bharat, MD, MBBS, FACS, allowed Cornelia Tischmacher to receive a double lung transplant for her stage IV lung cancer.

RET rechallenge following disease progression demonstrated greater efficacy with select combination therapies targeting bypass resistance vs single agents.

Rechallenge With RET Inhibitors Shows Efficacy in Pretreated NSCLC

Roman Fabbricatore
June 4th 2025
Article

RET rechallenge following disease progression demonstrated greater efficacy with select combination therapies targeting bypass resistance vs single agents.